Atlas Trials

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT06678230 · UNKNOWN

Trial details

NCT number
NCT06678230
Sponsor
The First Hospital of Jilin University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2024-11-01
Primary completion
2025-10-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.